Research Analysts’ updated eps estimates for Thursday, November 7th:
Arbutus Biopharma (NASDAQ:ABUS) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $5.00 price target on the stock.
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $28.00 price target on the stock.
Afentra (LON:AET) had its buy rating reissued by analysts at Shore Capital.
Alector (NASDAQ:ALEC) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $35.00 target price on the stock.
Aligos Therapeutics (NASDAQ:ALGS) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $75.00 target price on the stock.
AMC Entertainment (NYSE:AMC) had its hold rating reissued by analysts at Benchmark Co..
AppLovin (NASDAQ:APP) had its hold rating reaffirmed by analysts at Needham & Company LLC.
AppLovin (NASDAQ:APP) had its sell rating reissued by analysts at Benchmark Co.. They currently have a $66.00 target price on the stock.
AppLovin (NASDAQ:APP) had its outperform rating reaffirmed by analysts at Wedbush. The firm currently has a $270.00 price target on the stock, up from their previous price target of $170.00.
Arhaus (NASDAQ:ARHS) had its outperform rating reaffirmed by analysts at Telsey Advisory Group. The firm currently has a $12.00 price target on the stock.
ARM (NASDAQ:ARM) had its hold rating reiterated by analysts at Needham & Company LLC.
Arcutis Biotherapeutics (NASDAQ:ARQT) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $18.00 price target on the stock.
AstraZeneca (LON:AZN) had its buy rating reissued by analysts at Shore Capital.
Beam Therapeutics (NASDAQ:BEAM) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $80.00 target price on the stock.
Bumble (NASDAQ:BMBL) had its neutral rating reissued by analysts at Piper Sandler. They currently have a $8.00 target price on the stock, up from their previous target price of $7.00.
Boston Properties (NYSE:BXP) had its sector perform rating reissued by analysts at Scotiabank. Scotiabank currently has a $85.00 price target on the stock.
Cardlytics (NASDAQ:CDLX) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Avid Bioservices (NASDAQ:CDMO) had its sector perform rating reissued by analysts at Royal Bank of Canada. They currently have a $12.50 target price on the stock, up from their previous target price of $12.00.
Avid Bioservices (NASDAQ:CDMO) had its market perform rating reiterated by analysts at William Blair.
Coherus BioSciences (NASDAQ:CHRS) had its buy rating reissued by analysts at HC Wainwright. They currently have a $12.00 target price on the stock.
Traeger (NYSE:COOK) had its outperform rating reissued by analysts at Telsey Advisory Group. They currently have a $4.00 price target on the stock.
Core Scientific (NASDAQ:CORZ) had its buy rating reissued by analysts at Canaccord Genuity Group Inc.. They currently have a $17.00 price target on the stock.
Coya Therapeutics (NASDAQ:COYA) had its buy rating reiterated by analysts at Chardan Capital. They currently have a $14.00 price target on the stock.
Dine Brands Global (NYSE:DIN) had its outperform rating reiterated by analysts at Wedbush. They currently have a $47.00 price target on the stock.
Denali Therapeutics (NASDAQ:DNLI) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $90.00 target price on the stock.
DSW Capital (LON:DSW) had its house stock rating reissued by analysts at Shore Capital.
e.l.f. Beauty (NYSE:ELF) had its overweight rating reiterated by analysts at Piper Sandler. The firm currently has a $165.00 target price on the stock, up from their previous target price of $162.00.
Enovis (NYSE:ENOV) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $65.00 price target on the stock.
Evolus (NASDAQ:EOLS) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $27.00 target price on the stock.
Evotec (NASDAQ:EVO) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $8.00 target price on the stock.
Franklin Covey (NYSE:FC) had its outperform rating reiterated by analysts at Barrington Research. The firm currently has a $45.00 price target on the stock.
Fair Isaac (NYSE:FICO) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $2,040.00 target price on the stock.
Amicus Therapeutics (NASDAQ:FOLD) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Freshworks (NASDAQ:FRSH) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $20.00 target price on the stock.
Guild (NYSE:GHLD) had its outperform rating reissued by analysts at Wedbush. They currently have a $20.00 price target on the stock.
Gilead Sciences (NASDAQ:GILD) had its hold rating reiterated by analysts at Needham & Company LLC.
Genco Shipping & Trading (NYSE:GNK) had its buy rating reissued by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $25.00 price target on the stock.
Helios Towers (LON:HTWS) had its buy rating reissued by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 195 ($2.54) price target on the stock.
Ionis Pharmaceuticals (NASDAQ:IONS) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $60.00 price target on the stock.
iRobot (NASDAQ:IRBT) had its hold rating reissued by analysts at Needham & Company LLC.
ITV (LON:ITV) had its buy rating reaffirmed by analysts at Shore Capital.
Janux Therapeutics (NASDAQ:JANX) had its overweight rating reissued by analysts at Cantor Fitzgerald. They currently have a $100.00 price target on the stock.
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $207.00 target price on the stock.
Kinovo (LON:KINO) had its buy rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They currently have a GBX 95 ($1.24) target price on the stock.
Kitwave Group (LON:KITW) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. They currently have a GBX 495 ($6.44) target price on the stock.
Kaltura (NASDAQ:KLTR) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $3.00 target price on the stock.
Keros Therapeutics (NASDAQ:KROS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $100.00 target price on the stock.
Keros Therapeutics (NASDAQ:KROS) had its outperform rating reaffirmed by analysts at Wedbush. The firm currently has a $84.00 price target on the stock.
CS Disco (NYSE:LAW) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $8.00 target price on the stock.
Laird Superfood (NYSEAMERICAN:LSF) had its buy rating reissued by analysts at Roth Mkm. Roth Mkm currently has a $12.00 target price on the stock, up from their previous target price of $8.00.
Lyft (NASDAQ:LYFT) had its hold rating reissued by analysts at Needham & Company LLC.
Lyft (NASDAQ:LYFT) had its overweight rating reiterated by analysts at Piper Sandler. They currently have a $23.00 price target on the stock, up from their previous price target of $17.00.
Lyft (NASDAQ:LYFT) had its hold rating reissued by analysts at Benchmark Co..
Lyft (NASDAQ:LYFT) had its neutral rating reaffirmed by analysts at Wedbush. Wedbush currently has a $20.00 price target on the stock, up from their previous price target of $12.00.
MercadoLibre (NASDAQ:MELI) had its outperform rating reiterated by analysts at Wedbush. They currently have a $2,200.00 price target on the stock, up from their previous price target of $2,000.00.
MFA Financial (NYSE:MFA) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $15.00 target price on the stock.
MarketAxess (NASDAQ:MKTX) had its neutral rating reissued by analysts at Piper Sandler. Piper Sandler currently has a $265.00 target price on the stock.
Mogo (NASDAQ:MOGO) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $6.00 price target on the stock.
Match Group (NASDAQ:MTCH) had its neutral rating reiterated by analysts at Bank of America Co.. Bank of America Co. currently has a $35.00 price target on the stock, down from their previous price target of $50.00.
NewAmsterdam Pharma (NASDAQ:NAMS) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $36.00 price target on the stock.
Nuvation Bio (NYSE:NUVB) had its outperform rating reiterated by analysts at Wedbush. They currently have a $5.00 target price on the stock.
Navigator (NYSE:NVGS) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $20.00 target price on the stock.
Olaplex (NASDAQ:OLPX) had its market perform rating reiterated by analysts at Telsey Advisory Group. The firm currently has a $3.00 target price on the stock.
Palo Alto Networks (NASDAQ:PANW) had its negative rating reissued by analysts at OTR Global.
Perion Network (NASDAQ:PERI) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Praxis Precision Medicines (NASDAQ:PRAX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $120.00 target price on the stock.
Praxis Precision Medicines (NASDAQ:PRAX) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $151.00 price target on the stock.
Personalis (NASDAQ:PSNL) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $7.25 target price on the stock.
Paycor HCM (NASDAQ:PYCR) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $20.00 target price on the stock.
Papa Johns International (NASDAQ:PZZA) had its overweight rating reaffirmed by analysts at Stephens. Stephens currently has a $62.00 target price on the stock.
QUALCOMM (NASDAQ:QCOM) had its buy rating reaffirmed by analysts at Benchmark Co.. Benchmark Co. currently has a $240.00 target price on the stock.
QUALCOMM (NASDAQ:QCOM) had its neutral rating reiterated by analysts at Cantor Fitzgerald. The firm currently has a $160.00 price target on the stock.
Q2 (NYSE:QTWO) had its buy rating reissued by analysts at Truist Financial Co.. The firm currently has a $100.00 price target on the stock, up from their previous price target of $78.00.
Retail Opportunity Investments (NASDAQ:ROIC) had its neutral rating reissued by analysts at Robert W. Baird. They currently have a $17.50 price target on the stock, up from their previous price target of $16.00.
Rolls-Royce Holdings plc (LON:RR) had its buy rating reiterated by analysts at Shore Capital.
Recursion Pharmaceuticals (NASDAQ:RXRX) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $11.00 target price on the stock.
SAB Biotherapeutics (NASDAQ:SABS) had its buy rating reiterated by analysts at Chardan Capital. Chardan Capital currently has a $25.00 price target on the stock.
J Sainsbury (LON:SBRY) had its house stock rating reissued by analysts at Shore Capital.
Urban Logistics REIT (LON:SHED) had its buy rating reaffirmed by analysts at Shore Capital.
Steven Madden (NASDAQ:SHOO) had its market perform rating reiterated by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $50.00 price target on the stock.
Solid Biosciences (NASDAQ:SLDB) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $16.00 target price on the stock.
Sportradar Group (NASDAQ:SRAD) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $16.00 price target on the stock.
Surmodics (NASDAQ:SRDX) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Sarepta Therapeutics (NASDAQ:SRPT) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $205.00 target price on the stock.
SouthState (NASDAQ:SSB) had its outperform rating reiterated by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $120.00 target price on the stock, up from their previous target price of $115.00.
Taseko Mines (LON:TKO) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. The firm currently has a GBX 275 ($3.58) price target on the stock.
Tapestry (NYSE:TPR) had its outperform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $54.00 target price on the stock.
Trainline (LON:TRN) had its buy rating reiterated by analysts at Shore Capital.
Upwork (NASDAQ:UPWK) had its overweight rating reaffirmed by analysts at Piper Sandler. They currently have a $18.00 target price on the stock, up from their previous target price of $13.00.
U.S. Physical Therapy (NYSE:USPH) had its outperform rating reaffirmed by analysts at Barrington Research. They currently have a $108.00 price target on the stock.
Vanquis Banking Group (LON:VANQ) had its house stock rating reiterated by analysts at Shore Capital.
Wolfspeed (NYSE:WOLF) had its overweight rating reissued by analysts at Piper Sandler. Piper Sandler currently has a $18.00 target price on the stock, down from their previous target price of $20.00.
Warby Parker (NYSE:WRBY) had its outperform rating reiterated by analysts at Telsey Advisory Group. They currently have a $19.00 price target on the stock.
Wolverine World Wide (NYSE:WWW) had its market perform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $15.00 price target on the stock.
Xencor (NASDAQ:XNCR) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $38.00 price target on the stock.
Zillow Group (NASDAQ:Z) had its hold rating reissued by analysts at Needham & Company LLC.
Zillow Group (NASDAQ:ZG) had its overweight rating reaffirmed by analysts at Piper Sandler. Piper Sandler currently has a $73.00 target price on the stock, up from their previous target price of $62.00.
Receive News & Ratings for Arbutus Biopharma Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Co and related companies with MarketBeat.com's FREE daily email newsletter.
